TRASTUZUMAB DERUXTECAN for Transitional cell carcinoma: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

There are 9 adverse event reports in the FDA FAERS database where TRASTUZUMAB DERUXTECAN was used for Transitional cell carcinoma.

Most Reported Side Effects for TRASTUZUMAB DERUXTECAN

Side Effect	Reports	%	Deaths	Hosp.
Death	384	14.3%	384	24
Off label use	258	9.6%	36	71
Nausea	251	9.4%	18	86
Myelosuppression	242	9.0%	0	98
Fatigue	186	6.9%	14	61
Malignant neoplasm progression	171	6.4%	48	29
Vomiting	140	5.2%	20	58
Diarrhoea	132	4.9%	23	68
Interstitial lung disease	130	4.8%	46	46
Pneumonitis	125	4.7%	41	48
Metastases to central nervous system	103	3.8%	22	25
Toxicity to various agents	97	3.6%	2	15
Asthenia	95	3.5%	13	40
Disease progression	87	3.2%	29	14
Dyspnoea	77	2.9%	23	38